Cagrilintide
Cagrilintide (10mg)
$150USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.241
Reference number
10mg
Lyophilized vial
Long-acting amylin analog. In clinical trials in combination with semaglutide (CagriSema) for metabolic research.
Origin
Cagrilintide was developed by Novo Nordisk as a long-acting acylated amylin analog. Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells, first identified by Westermark et al. in 1987. Cagrilintide was engineered with fatty acid acylation to extend its duration of action for once-weekly administration.
Research Lineage
Enebo et al. published Phase II clinical trial results in 2021. Novo Nordisk is advancing CagriSema (cagrilintide + semaglutide) through Phase III trials for obesity and type 2 diabetes. The combination approach targets two complementary satiety pathways — amylin and GLP-1 — representing a dual-agonist strategy in metabolic research.
Mechanism of Action
Cagrilintide activates amylin receptors (AMY1, AMY2, AMY3), which are calcitonin receptor/RAMP heterodimers in the area postrema and hypothalamus. Amylin receptor activation has been observed to slow gastric emptying and modulate appetite signaling. The fatty acid acylation enables albumin binding, extending the pharmacokinetic half-life to support weekly dosing.
Structural Notes
Acylated amylin analog. C18 fatty diacid modification for albumin binding. Extended half-life (~7 days) compared to native amylin (~15 minutes).
Key References
Enebo LB et al. Lancet. 2021;397(10286):1736-48.
Westermark P et al. Proc Natl Acad Sci USA. 1987;84(11):3881-5.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.